Search alternatives:
largest decrease » larger decrease (Expand Search), marked decrease (Expand Search)
latest decrease » greatest decrease (Expand Search), largest decreases (Expand Search), latency decreased (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
i largest » _ largest (Expand Search), i large (Expand Search)
a latest » a latent (Expand Search), _ latest (Expand Search), _ latent (Expand Search)
largest decrease » larger decrease (Expand Search), marked decrease (Expand Search)
latest decrease » greatest decrease (Expand Search), largest decreases (Expand Search), latency decreased (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
i largest » _ largest (Expand Search), i large (Expand Search)
a latest » a latent (Expand Search), _ latest (Expand Search), _ latent (Expand Search)
-
1
-
2
-
3
Inhibition of NEAT1 decreased the miR-204-5p expression and increased Six1 expression.
Published 2024“…<p>(A) NEAT1 expression following siRNA transfection in BEAS-2B cells; (B-D) The expression of NEAT1, miR-204-5p, and Six1 after decreasing NEAT1 expression. * p <0.05, *** p < 0.001, and **** p <0.0001.…”
-
4
-
5
-
6
-
7
-
8
-
9
-
10
-
11
-
12
-
13
-
14
-
15
A summary of the included study characteristics.
Published 2025“…The results show that one month after the NSPT, there was no significant difference in the mean visfatin level of GCF (SMD: -3.91, 95%CI: -9.83, 2.01, p = 0.195, I-square, 96.6%, random effect model, n = 2) and serum (SMD: -0.33, 95%CI: -0.98, 0.33, p = 0.332, fixed effect model, n = 1), but 2, 3 and 6 months after NSPT, the mean visfatin level of GCF and serum decreased significantly. There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”
-
16
-
17
-
18
Table 1_Imeglimin may affect hemoglobin A1c accuracy via prolongation of erythrocyte lifespan in patients with type 2 diabetes mellitus: insights from the INFINITY clinical trial.d...
Published 2025“…</p>Results<p>The change in hemoglobin concentration at 6 months was not statistically significant (mean ± SD: −0.2 ± 0.9 g/dL; p = 0.23). While HbA1c and GA decreased and 1,5-AG increased one month after imeglimin initiation, GA and 1,5-AG showed rapid changes compared to the gradual decrease in HbA1c. …”
-
19
-
20